Raymond James Financial
GYRE icon

Raymond James Financial’s Gyre Therapeutics GYRE Stock Holding History

Raymond James Financial’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-650
Closed -$4.78K – 5713
2025
Q2 		$4.78K Buy
+650
New +$5.67K ﹤0.01% 6186

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Raymond James Financial's GYRE Position: Q3 2025 in Review

Raymond James Financial sold out of Gyre Therapeutics (GYRE) in Q3 2025, closing a stake of 650 shares — an estimated $4.78K sold.

Raymond James Financial first reported a position in GYRE in Q2 2025 and held it in 1 quarter. The position peaked at $4.78K in Q2 2025. 48 funds tracked by Wall St. Rank hold GYRE as of Q3 2025.

  • Raymond James Financial reported no remaining Gyre Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 650 Gyre Therapeutics shares in Q3 2025, an estimated $4.78K.
  • Raymond James Financial first reported a position in Gyre Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's Gyre Therapeutics position peaked at $4.78K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.